Defibrotide is currently the safest and most effective drug approved for the prevention and treatment of hepatic sinusoidal obstruction syndrome (HSOS) following hematopoietic stem cell transplantation (HSCT); it is the only drug approved in the United States for the treatment of HSCT-associated HSOS with renal or pulmonary dysfunction, and is approved in the European Union for the treatment of severe HSOS post-HSCT. It is also the first therapy approved by the U.S. FDA for the treatment of severe hepatic veno-occlusive disease (VOD) in both adults and children.